Panuveitis induced by brentuximab vedotin: a possible novel adverse event of an antibody-drug conjugate

Leuk Lymphoma. 2022 Jan;63(1):239-242. doi: 10.1080/10428194.2021.1978090. Epub 2021 Sep 13.

Authors

Philippos Apolinario Costa¹, Andrea Patricia Espejo-Freire², Kenneth Chen Fan³, Thomas Arno Albini³, Georgios Pongas²

Affiliations

¹ Department of Medicine, Division of Internal Medicine, University of Miami Miller School of Medicine, Miami, FL, USA.
² Department of Medicine, Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
³ Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL, USA.

PMID: 34514943
DOI: 10.1080/10428194.2021.1978090

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Brentuximab Vedotin* / adverse effects
Hodgkin Disease*
Humans
Immunoconjugates* / adverse effects
Ki-1 Antigen
Panuveitis* / chemically induced

Substances

Immunoconjugates
Ki-1 Antigen
Brentuximab Vedotin